Cytosorbents Corp (CTSO)

Trade CTSO now with
4/5/2022 7:02:47 AM CytoSorbents Appoints Jiny Kim To Board
2/1/2022 7:17:08 AM CTSO : First Patient Enrolled In Trial Evaluating CytoSorb To Restore Hemodynamic Stability In Refractory Septic Shock
1/24/2022 8:24:21 AM New Publication Reports Reductions In Bleeding Complications Following Acute Aortic Dissection Surgery Using CTSO' Tech
1/18/2022 7:08:06 AM CytoSorbents Reports Preliminary 2021 Product Sales About $40.1 Mln, Inclg Core Non-COVID-19 Sales Growth Of 13%
12/21/2021 7:12:49 AM CytoSorbents Appoints Daniel Wendt As VP, Medical Affairs Cardiovascular
12/20/2021 7:14:24 AM CytoSorbents Publishes CTC Multicenter Registry Results Using CytoSorb In Critically Ill COVID-19 Patients On ECMO
10/20/2021 7:09:13 AM CytoSorbents : No Signal For Harm Due To Use Of CytoSorb In Patients Undergoing Surgery For Infective Endocarditis
10/14/2021 7:12:33 AM CytoSorbents : First Patient Enrolled In U.S. STAR-T Trial Evaluating DrugSorb-ATR Antithrombotic Removal System
9/10/2021 7:16:20 AM CytoSorbents Announces Filing Of IDE Application To Gain FDA Approval To Conduct Clinical Study, STAR-D
9/1/2021 7:12:59 AM CytoSorbents Presents Topline Results From CytoSorb Therapy In COVID-19 Multicenter Registry At ISICEM 2021
8/30/2021 7:10:08 AM CytoSorbents, Aferetica Unveil Launch Of PerSorb Adsorber And PerLife Organ Perfusion System In Italy
8/12/2021 7:14:38 AM CytoSorbents: FDA Grants Second Breakthrough Device Designation For DrugSorb-ATR Antithrombotic Removal System
7/6/2021 7:06:19 AM CytoSorbents Receives Full FDA Approval Of Investigational Device Exemption (IDE) For U.S. STAR-T Trial